Ipamorelin has been given to people in early clinical studies, so human exposure is documented. However, the tested Phase 2 indication did not show the hoped-for benefit, and lifestyle claims such as fat loss, muscle gain or anti-ageing remain unproven.
Still uncertain: Muscle gain, fat loss, recovery, anti-ageing benefit, safe chronic subcutaneous use or a validated wellness dose.
By confirming your subscription, you agree to receive occasional WhichPeps Evidence Updates. Kit processes the signup and email delivery for WhichPeps. Privacy. Unsubscribe anytime.
What does the evidence mean in simple terms? table
What is it?
Ghrelin-receptor/GH secretagogue peptide
Entity type
Peptide
Research focus
GH-axis physiology and motility research
Human evidence
Human evidence includes early PK/GH-response studies and a randomized Phase II postoperative-ileus trial. In that trial, IV ipamorelin 0.03 mg/kg twice daily did not significantly improve the primary or key secondary efficacy endpoints versus placebo.
Regulatory status
Not FDA-approved; FDA lists safety concerns for compounded ipamorelin.
Main limitations
Muscle gain, fat loss, recovery, anti-ageing benefit, safe chronic subcutaneous use or a validated wellness dose.
Safety
FDA notes immunogenicity/impurity concerns and serious adverse events in an IV gastric-motility study, including deaths, with insufficient information for other injection uses.
Evidence reviewed
2026-09-18
i
Human evidence includes early PK/GH-response studies and a randomized Phase II postoperative-ileus trial. In that trial, IV ipamorelin 0.03 mg/kg twice daily did not significantly improve the primary or key secondary efficacy endpoints versus placebo.
Outcome-level evidence
Evidence is not one score.
Each record below answers a narrower question about an outcome, population or context. Evidence status and the study finding are shown separately so strong evidence is not mistaken for a positive effect.
Median time was 25.3 hours with ipamorelin versus 32.6 hours placebo; difference was not statistically significant (P=0.15). Key and secondary efficacy analyses were not significant.
FDA notes immunogenicity/impurity concerns and serious adverse events in an IV gastric-motility study, including deaths, with insufficient information for other injection uses.
FDA cites serious adverse events in the IV clinical programme and says adequate safety information for other injectable routes is lacking; compounded-product impurity and immunogenicity issues also matter.
Technical details
Mechanism / biologyAgonist at the growth-hormone secretagogue receptor, producing a pulse of GH release.
Route / formulation boundaryThe Phase II evidence was intravenous in postoperative patients and cannot be transferred to subcutaneous wellness/bodybuilding use.
Identity / data-quality noteUse the canonical compound identity and studied formulation when interpreting evidence.
Study / label regimen evidenceVerified study/label regimen evidence is available. Published human pharmacology regimen. Open descriptive regimen evidence →
WhichPeps does not rely on a single headline study when the evidence base is broader. Primary research, registries, regulators and supporting records are kept distinct.
2structured study records
4outcome records
6linked source records
How to read these counts: they show evidence coverage, not evidence strength. One large, well-designed study can be more informative than several weak or indirect records.
Show supporting and discovery sources
Study pages above contain the records used for public evidence summaries. The links below include supporting, regulatory and literature-discovery sources; a registry or search result is not treated as proof of benefit.
Evidence rule: WhichPeps keeps human, animal, laboratory, regulatory and product/formulation evidence distinct. Common names help people find the page; they do not change the underlying scientific identity.
